Epigenetics: Time to translate into transplantation

Transplantation

Volumn 94, Issue 1, 2012, Pages 1-7

  McCaughan, Jennifer A ^a   McKnight, Amy Jayne ^a   Courtney, Aisling E ^a   Maxwell, Alexander P ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Epigenetic; Histone; Methylation; miRNA; Transplant

Indexed keywords

AZATHIOPRINE; CYTOKINE; DNA; DNA METHYLTRANSFERASE 1; FR 276457; GLUCOCORTICOID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN RASAL1; RAS PROTEIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CARDIAC GRAFT REJECTION; CPG ISLAND; CYTOKINE PRODUCTION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FIBROSING ALVEOLITIS; GENE EXPRESSION REGULATION; GRAFT SURVIVAL; HISTONE MODIFICATION; HUMAN; IMMUNOGENETICS; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RNA INTERFERENCE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TRANSPLANTATION;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ORGAN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84863728633     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824db9bd     Document Type: Review

References (104)

1. Dwivedi RS, Herman JG, McCaffrey TA, et al. Beyond genetics: Epigenetic code in chronic kidney disease. Kidney Int 2010; 79: 23.
2. Callinan PA, Feinberg AP. The emerging science of epigenomics. Hum Mol Genet 2006; 15: R95.
3. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102: 10604.
4. Sterling WA, Aldrete JS, Cobbs CG, et al. Treatment of end-stage renal disease by transplantation: Clinical results with 111 cases. Am Surg 1975; 41: 4.
5. Courtney AE, McNamee PT, Maxwell AP. The evolution of renal transplantation in clinical practice: For better, for worse? QJM 2008; 101: 967.
6. Moore J, McKnight AJ, Simmonds MJ, et al. Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA 2010; 303: 1282.
7. Morgun A, Shulzhenko N, Rampim GF, et al. Interleukin-2 gene polymorphism is associated with renal but not cardiac transplant outcome. Transplant Proc 2003; 35: 1344.
8. Thakkinstian A, Dmitrienko S, Gerbase-Delima M, et al. Association between cytokine gene polymorphisms and outcomes in renal transplantation: A meta-analysis of individual patient data. Nephrol Dial Transplant 2008; 23: 3017.
9. Bell CG, Finer S, Lindgren CM, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One 2010; 5: e14040.
10. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654.
11. Lamarck JBP, AdCdM. Philosophie zoologique: Ou Exposition des considaerations relative áa l'histoire naturelle des animaux. Paris: Dentu et L'Auteur; 1809.
12. Heijmans BT, Tobi EW, Lumey LH, et al. The epigenome: Archive of the prenatal environment. Epigenetics 2009; 4: 526.
13. Roseboom TJ, van der Meulen JH, Osmond C, et al. Coronary heart disease after prenatal exposure to the Dutch famine, 1944Y45. Heart 2000; 84: 595.
14. Okano M, Bell DW, Haber DA, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247.
15. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128: 669.
16. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 2000; 97: 5237.
17. Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: Molecular mechanisms and implications for disease. Trends Mol Med 2010; 16: 7.
18. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299.
19. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol 2003; 109: 37.
20. Hagmann CA, Schildberg FA, Tolba RH. Epigenetics and transplantation: Clinical applications of chromatin regulation. Discov Med 2010; 10: 511.
21. van den Elsen PJ, Holling TM, van der Stoep N, et al. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin Immunol 2003; 109: 46.
22. Lippman Z, Martienssen R. The role of RNA interference in heterochromatic silencing. Nature 2004; 431: 364.
23. Gupta R, Nagarajan A, Wajapeyee N. Advances in genome-wide DNA methylation analysis. Biotechniques 2010; 49: 3.
24. Naesens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010; 6: 614.
25. Lodish HF, Zhou B, Liu G, et al. Micromanagement of the immune system by microRNAs. Nat Rev Immunol 2008; 8: 120.
26. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 2008; 9: 102.
27. Kozomara A, Griffiths-Jones S. miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: D152.
28. Sato F, Tsuchiya S, Meltzer SJ, et al. MicroRNAs and epigenetics. FEBS J 2011; 278: 1598.
29. Shan J, Feng L, Luo L, et al. MicroRNAs: Potential biomarker in organ transplantation. Transpl Immunol 2011; 24: 210.
30. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011; 11: 2221.
31. Amor DJ, Halliday J. A review of known imprinting syndromes and their association with assisted reproduction technologies. Hum Reprod 2008; 23: 2826.
32. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455. (Pubitemid 36444319)
33. Jin B, Tao Q, Peng J, et al. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum Mol Genet 2008; 17: 690.
34. Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 2007; 318: 1469.
35. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: An important mechanism in inflammatory lung diseases. COPD 2005; 2: 445.
36. Phe V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010; 105: 1364.
37. Napieralski R, Brunner N, Mengele K, et al. Emerging biomarkers in breast cancer care. Biomark Med 2010; 4: 505.
38. Corvalan AH, Maturana MJ. Recent patents of DNA methylation biomarkers in gastrointestinal oncology. Recent Pat DNA Gene Seq 2010; 4: 202.
39. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011; 117: 2690.
40. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010; 116: 129.
41. Suzuki M, Sunaga N, Shames DS, et al. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 2004; 64: 3137.
42. Schroeder M, Krebs MO, Bleich S, et al. Epigenetics and depression: Current challenges and new therapeutic options. Curr Opin Psychiatry 2010; 23: 588.
43. Gavin DP, Sharma RP. Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 2010; 34: 882.
44. Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylationVA novel risk factor for cardiovascular disease? J Intern Med 2007; 261: 488.
45. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544.
46. Braun WE. Long-term results in 35 HLA-identical sibling and 3 HLA identical parentYchild renal allograft recipients. Nephron 1978; 22: 232.
47. Moreira P, Sá H, Figueiredo A, et al. Delayed renal graft function: Risk factors and impact on the outcome of transplantation. Transplant Proc 2011; 43: 100.
48. Parker MD, Chambers PA, Lodge JP, et al. Ischemia-reperfusion injury and its influence on the epigenetic modification of the donor kidney genome. Transplantation 2008; 86: 1818.
49. Pratt JR, Parker MD, Affleck LJ, et al. Ischemic epigenetics and the transplanted kidney. Transplant Proc 2006; 38: 3344.
50. Granger A, Abdullah I, Huebner F, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008; 22: 3549.
51. Zager RA, Johnson AC, Becker K. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and 'end stage' kidney disease. Am J Physiol Renal Physiol 2011; 301: F1334.
52. Mehta TK, Hoque MO, Ugarte R, et al. Quantitative detection of promoter hypermethylation as a biomarker of acute kidney injury during transplantation. Transplant Proc 2006; 38: 3420.
53. ZhangW, Zhou L, DingSM, et al. Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation. Oncol Rep 2011; 25: 1053.
54. Nourse JP, Jones K, Gandhi MK. Epstein-Barr Virus-related posttransplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant 2011; 11: 888.
55. Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol 2000; 53: 238.
56. Rossi D, Gaidano G, Gloghini A, et al. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br J Haematol 2003; 123: 475.
57. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965.
58. Hsu CC, Li HP, Hung YH, et al. Targeted methylation of CMV and E1A viral promoters. Biochem Biophys Res Commun 2010; 402: 228.
59. Liu XF, Yan S, Abecassis M, et al. Establishment of murine cytomegalovirus latency in vivo is associated with changes in histone modifications and recruitment of transcriptional repressors to the major immediate-early promoter. J Virol 2008; 82: 10922.
60. Lambert MP, Paliwal A, Vaissière T, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011; 54: 705.
61. Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol 2010; 25: 61.
62. Batchelor JR, Lechler RI. Why MHC incompatible grafts induce strong primary alloimmunity. Transplant Proc 1982; 14: 535.
63. Kimber I, Cumberbatch M. Stimulation of Langerhans cell migration by tumor necrosis factor alpha (TNF-alpha). J Invest Dermatol 1992; 99: 48S.
64. Warrens AN, Lombardi G, Lechler RI. Presentation and recognition of major and minor histocompatibility antigens. Transpl Immunol 1994; 2: 103.
65. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: Directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562.
66. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006; 27: 405.
67. Barrett M, Milton AD, Barrett J, et al. Needle biopsy evaluation of class II major histocompatibility complex antigen expression for the differential diagnosis of cyclosporine nephrotoxicity from kidney graft rejection. Transplantation 1987; 44: 223.
68. Kinugasa F, Nagatomi I, Nakanishi T, et al. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl Immunol 2009; 21: 198.
69. Kinugasa F, Yamada T, Noto T, et al. Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol Pharm Bull 2008; 31: 1723.
70. Xiang J, Gu X, Qian S, et al. Endoplasmic reticulum stress-mediated apoptosis involved in indirect recognition pathway blockade induces long-term heart allograft survival. J Biomed Biotechnol 2010; 2010: 705431.
71. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359.
72. Smith KG, Clatworthy MR. Fc gamma RIIB in autoimmunity and infection: Evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10: 328.
73. Parra M. Epigenetic events during B lymphocyte development. Epigenetics 2009; 4: 468.
74. Wolf M, Schimpl A, Hunig T. Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(j) and CD4(+)CD25(+) T cells: Evidence for two distinct regulatory mechanisms. Eur J Immunol 2001; 31: 1637.
75. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665.
76. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398.
77. Iwase H, Kobayashi T, Kodera Y, et al. Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation. Transplantation 2011; 91: 191.
78. Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol 2010; 6: 577.
79. Huehn J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: The key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009; 9: 83.
80. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009; 114: 3727.
81. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
82. van Loosdregt J, Vercoulen Y, Guichelaar T, et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010; 115: 965.
83. Chen C, Rowell EA, Thomas RM, et al. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 2006; 281: 36828.
84. Iwata H, Sato H, Suzuki R, et al. A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol 2011; 38: 1653.
85. Mitmaker EJ, Griff NJ, Grogan RH, et al. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 2011; 149: 504.
86. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: Present knowledge and future perspectives. Transplantation 2004; 78: 311.
87. Mendoza JL, Urcelay E, Lana R, et al. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13: 585.
88. Kuypers DR, de Jonge H, Naesens M, et al. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010; 32: 2012.
89. Gensburger O, Van Schaik RH, Picard N, et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics 2010; 20: 537.
90. Kagaya H, Miura M, Saito M, et al. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin Pharmacol Toxicol 2010; 107: 631.
91. Michelon H, König J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010; 11: 1703.
92. Jacobson PA, Schladt D, Oetting WS, et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation 2011; 91: 309.
93. Krukowski K, Eddy J, Kosik KL, et al. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification. Brain Behav Immun 2011; 25: 239.
94. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006; 27: 405.
95. Cuddapah S, Barski A, Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr Opin Immunol 2010; 22: 341.
96. Gold M, Hurwitz J, Anders M. The enzymatic methylation of RNA and DNA. Biochem Biophys Res Commun 1963; 11: 107.
97. Chalfie M, Horvitz HR, Sulston JE. Mutations that lead to reiterations in the cell lineages of C. elegans. Cell 1981; 24: 59.
98. Bird A, Taggart M, Frommer M, et al. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 1985; 40: 91.
99. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843.
100. Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408: 86.
101. Zeng L, Kanwar YS, Amro N, et al. Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy. Kidney Int 2003; 63: 2094.
102. Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004; 32: e188.
103. Sui W, Dai Y, Huang Y, et al. Microarray analysis of MicroRNA expression in acute rejection after renal transplantation. Transpl Immunol 2008; 19: 81.
104. Rakyan VK, Down TA, Balding DJ, et al. Epigenome-wide association studies for common human diseases. Nat Rev Genet 201; 12: 529.